Takeda Pharmaceutical Company (TAKN) Stock Price & Analysis
TAKN Stock Chart & Stats
- Day’s Range
- MXN 345.00 - MXN 345.00
- 52-Week Range
- MXN 226.00 - MXN 345.00
- Previous Close
- MXN 345.00
- Volume
- 0
- Average Volume (3M)
- 5
- Market Cap
- MXN 1.26T
- Enterprise Value
- MXN 85.30B
- Total Cash (Recent Filing)
- MXN 454.40B
- Total Debt (Recent Filing)
- MXN 4.58T
- Price to Earnings (P/E)
- 27.2
- Beta
- 0.25
- Next Earnings
- Jan 28, 2027 (Est.)
- EPS Estimate
- 5.3
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.45%
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Operating Profitability
Takeda combines sustained multi-year revenue growth with strong gross and operating profitability, indicating a substantial commercial base across its therapeutic franchises. These economics can support continued research investment, product launches, and resilience as individual medicines mature.
Expanding New-Product Pipeline
Rapid growth from recently launched products provides an avenue to replace aging medicines and diversify Takeda’s revenue base. Continued launches across narcolepsy, hematology and immunology could strengthen future growth if clinical, regulatory and commercial momentum persists.
Transformation Savings
A sizable, operationally tracked savings program can improve cost discipline and help fund research and commercial investment. Progress on procurement and the broader transformation may support operating profitability over the next several quarters, even while Takeda absorbs restructuring costs.
Bears Say
Mature Portfolio Revenue Pressure
Patent-related erosion and weakness in mature products create a continuing revenue replacement challenge rather than a temporary sales fluctuation. Takeda must scale newer medicines quickly enough to offset declining established brands, which can pressure growth and mix.
Weakening Cash-Flow Momentum
Positive cash generation remains an asset, but declining free cash flow and relatively light operating-cash conversion reduce financial predictability. Weaker cash momentum could constrain flexibility for acquisitions, pipeline investment, shareholder returns, or restructuring commitments.
Zasocitinib IBD Development Uncertainty
Uncertainty around dose response and the Phase III path weakens visibility for a potentially important pipeline asset. Additional data and development decisions may delay commercialization, increase investment needs, and leave future growth more dependent on other launches.
Takeda Pharmaceutical Company News
TAKN FAQ
What was Takeda Pharmaceutical Company’s price range in the past 12 months?
What is Takeda Pharmaceutical Company’s market cap?
When is Takeda Pharmaceutical Company’s upcoming earnings report date?
How were Takeda Pharmaceutical Company’s earnings last quarter?
Is Takeda Pharmaceutical Company overvalued?
Does Takeda Pharmaceutical Company pay dividends?
What is Takeda Pharmaceutical Company’s EPS estimate?
How many shares outstanding does Takeda Pharmaceutical Company have?
What happened to Takeda Pharmaceutical Company’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Takeda Pharmaceutical Company?
What is the TipRanks Smart Score and how is it calculated?
Takeda Pharmaceutical Company Stock Smart Score
Company Description
Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Julie So-Young Kim
- Employees
- 47,029
- Website
- www.takeda.com
- Address
- 1-1, Nihonbashi-Honcho 2-chome, Tokyo, OS, 103-8668, JP
Takeda Pharmaceutical Company (TAKN) Earnings & Revenues
TAKN Company Deck
TAKN Earnings Call
Earnings Call SentimentPositive
The call was broadly positive. Takeda reported core operating profit growth, raised full-year core profit and EPS guidance, advanced multiple regulatory and pipeline milestones, launched ORZEYFUL and MIMRYLO, and highlighted strong results for ENTYVIO and TAK-921. These positives were tempered by a 1% constant-exchange-rate revenue decline, a 1.2% core EPS decline, mature-portfolio and albumin headwinds, lower adjusted free cash flow, developing reimbursement for new products, and uncertainty around zasocitinib's ulcerative colitis dose response. Highlights significantly outweighed the lowlights.
View all MX:TAKN earnings summariesTAKN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 4 | 1 |
| Technical Analysis | 4 | 2 | 1 |
| Moving Averages | 10 | 2 | 0 |
